Waist Circumference Independently Associated with Breast Cancer Risk
the Cancer Therapy Advisor take:
Overall adiposity was positively associated with overall breast cancer risk — specifically waist circumference with overall risk in premenopausal and postmenopausal women, according to an article published online in the journal Cancer.
Participants enrolled in the study from 2003 to 2009 included a total of 50,884 women in a Sister Study cohort (aged 35 to 74 years).
In order to be eligible to participate, the women must have had a sister previously diagnosed with breast cancer.
Results showed 2,009 breast cancer diagnoses were made during the follow-up period (mean=5.4 years). Overall breast cancer risk had positive associations with weight, body mass index (BMI), waist circumference, and waist-to-hip ratio.
Hazard ratios (HR) for these associations were greater among postmenopausal women, women with hormonally responsive tumors, and those not currently using postmenopausal hormones.
Furthermore, waist circumference correlations continued to be present after adjusting for BMI in both postmenopausal women (81-88 cm vs. ≤80 cm: HR = 1.16; 95% CI: 1.01, 1.35 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 1.10, 1.54) and premenopausal women (81-88 cm vs. ≤80 cm: HR = 1.56; 95% CI: 1.19, 2.04 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 0.91, 1.87).
Overall adiposity was positively associated with overall breast cancer risk in premenopausal and postmenopausal women.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear